Albert B. Sabin Vaccine Institute, Inc. (the)
Rank #795 of 1,000 by FY2025 federal contract value · Headquarters: WASHINGTON, DC
FY2025 contract value
$70,386,301
Oct 1, 2024 – Sep 30, 2025
FY2024 contract value
$20,310,632
FY2023 contract value
$0
Top agency (FY2025)
Department of Health and Human Services
$70,386,301
Company profile
- Legal name (as listed)
- ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)
- UEI
- H5E8NU6N2HZ5
- DUNS
- 849900175
- Headquarters
- WASHINGTON, DC
- Business types
- Category BusinessCorporate Entity Tax ExemptNonprofitOther Than Small BusinessSpecial DesignationsUS Owned Business
Contract value trend, FY2023 – FY2025
| Fiscal year | Contract value | Change vs prior year |
|---|---|---|
| FY2023 | $0 | — |
| FY2024 | $20,310,632 | — |
| FY2025 | $70,386,301 | +246.5% |
FY2025 breakdowns
Top 10 in each category by FY2025 contract value.
Top awarding agencies
| Department of Health and Human ServicesHHS | $70,386,301 |
Top places of performance (states)
| District Of ColumbiaDC | $70,386,301 |
Top industries (NAICS)
| Research and Development in Biotechnology (except Nanobiotechnology)541714 | $70,386,301 |
Top product & service codes (PSC)
| HEALTH R&D SERVICES; HEALTH CARE - OTHER; APPLIED RESEARCHAN42 | $70,386,301 |
| R&D- MEDICAL: SPECIALIZED MEDICAL SERVICES (ADVANCED DEVELOPMENT)AN73 | $0 |
Contract awards
Up to 20 awards with activity in FY2025, newest start date first. Amounts are individual award obligations, not company totals.
CONT_AWD_75A50123C00010_7505_-NONE-_-NONE-
$163,082,416
Awarding agency: Department of Health and Human Services
Description: THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI
Start date: Dec 29, 2022
NAICS: —
PSC: —
Place: DC
CONT_AWD_75A50119C00055_7505_-NONE-_-NONE-
$145,378,689
Awarding agency: Department of Health and Human Services
Description: THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE.
Start date: Sep 26, 2019
NAICS: —
PSC: —
Place: DC
NAICS and PSC are not reported for these awards in USAspending.
Source: USAspending.gov. Company totals are sums of all contract obligations across the company's USAspending recipient records for each fiscal year. This page is not affiliated with or endorsed by the U.S. government.